Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Usage of Baclofen for Sleep Improvement After Cardiac Surgery
NCT02529514 · University of Liege · PHASE4 · suspended · last registry update 2016-05-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, University of Liege |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABBR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2017-05-10Results posted on the registry: New York State Psychiatric Institute, Baclofen + Marijuana (NCT00373295)
- 2017-05-05Results posted on the registry: Essentia Health, Baclofen + Placebo (NCT01937364)
- 2017-05-05Also stopped (terminated): Essentia Health, Baclofen + Placebo (NCT01937364)
- 2017-01-27Results posted on the registry: Sha'ar Menashe Mental Health Center, Baclofen (NCT01002105)
- 2017-01-25Phase 3 first posted: Jazz Pharmaceuticals, JZP-258 (NCT03030599)
- 2017-01-18Phase 3 first posted: Pharnext S.C.A., PXT3003 (NCT03023540)
- 2016-10-06Also stopped (withdrawn): University of Missouri-Columbia, baclofen, intrathecal (NCT01352611)
- 2016-09-08Also stopped (withdrawn): University of Pennsylvania, Baclofen ER + Placebo (NCT02003664)
- 2016-08-17Phase 3 first posted: RVL Pharmaceuticals, Inc., arbaclofen ER Tablets + Placebo for arbaclofen ER tablets (NCT02869425)
- 2016-07-15Results posted on the registry: University of Rochester, Amitriptyline + Baclofen (NCT02099006)
- 2016-05-19Also stopped (terminated): University of Medicine and Dentistry of New Jersey, Placebo + Sodium Oxybate (NCT00498485)
- 2016-04-21Results posted on the registry: University of Medicine and Dentistry of New Jersey, Placebo + Sodium Oxybate (NCT00498485)
- 2016-03-30Phase 3 first posted: Nantes University Hospital, BACLOFEN + PLACEBO (NCT02723383)
- 2016-03-28Phase 3 first posted: Avadel, FT218 + Placebo (NCT02720744)
- 2016-02-08Results posted on the registry: Nathan Kline Institute for Psychiatric Research, Sodium Oxybate (NCT00594256)
- 2015-12-22Phase 3 first posted: Ramin Khatami, Sodium Oxybate + Placebo (NCT02637648)
- 2015-11-04Results posted on the registry: VA Office of Research and Development, Baclofen + Placebo (NCT00257894)
- 2015-11-04Also stopped (terminated): VA Office of Research and Development, Baclofen + Placebo (NCT00257894)
- 2015-08-21Also stopped (terminated): Gonzalez-Heydrich, Joseph, M.D., R-baclofen (NCT01172509)
- 2015-07-14Phase 3 first posted: Walter Reed National Military Medical Center, a drug against GABBR1 (NCT02497066)
- 2015-06-09Results posted on the registry: VA Office of Research and Development, baclofen + placebo (NCT01008280)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision